ADDME--Avoiding Drug Development Mistakes Early: Central Nervous System Drug Discovery Perspective

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2009 Jun 19

PMID 19534730

Citations 26

Authors

Katya Tsaioun

Michel Bottlaender

Aloise Mabondzo

Affiliations

Soon will be listed here.

Abstract

The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and its place in pharmaceutical development, and central nervous system drug discovery in particular. Assays that have been developed in response to specific needs and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of absorption and toxicity are discussed. The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity.

Citing Articles

A comprehensive review of artificial intelligence for pharmacology research.

Li B, Tan K, Lao A, Wang H, Zheng H, Zhang L Front Genet. 2024; 15:1450529.

PMID: 39290983 PMC: 11405247. DOI: 10.3389/fgene.2024.1450529.

Identification of echinoderm metabolites as potential inhibitors targeting wild-type and mutant forms of Escherichia coli RNA polymerase (RpoB) for tuberculosis treatment.

Alsulais F, Alhaidhal B, Mothana R, Alanzi A PLoS One. 2024; 19(8):e0304587.

PMID: 39213289 PMC: 11364244. DOI: 10.1371/journal.pone.0304587.

Insilico exploration C. koseri ATP synthase inhibitors by pharmacophore-based virtual screening, molecular docking and MD simulation.

Alanzi A, A Z A, Alhazzani K PLoS One. 2024; 19(8):e0308251.

PMID: 39173004 PMC: 11341028. DOI: 10.1371/journal.pone.0308251.

Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction.

Myung Y, de Sa A, Ascher D Nucleic Acids Res. 2024; 52(W1):W469-W475.

PMID: 38634808 PMC: 11223837. DOI: 10.1093/nar/gkae254.

A soft-computation hybrid method for search of the antibiotic-resistant gene in for promising drug target identification and antimycobacterial lead discovery.

Jaiswal N, Kumar A Bioinform Adv. 2023; 3(1):vbad090.

PMID: 37521310 PMC: 10382254. DOI: 10.1093/bioadv/vbad090.

References

Megard I, Garrigues A, Orlowski S, Jorajuria S, Clayette P, Ezan E . A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res. 2002; 927(2):153-67. DOI: 10.1016/s0006-8993(01)03337-6. View

Yang L, Soonpaa M, Adler E, Roepke T, Kattman S, Kennedy M . Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008; 453(7194):524-8. DOI: 10.1038/nature06894. View

Schinkel A, Smit J, van Tellingen O, Beijnen J, Wagenaar E, van Deemter L . Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77(4):491-502. DOI: 10.1016/0092-8674(94)90212-7. View

Kola I, Landis J . Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004; 3(8):711-5. DOI: 10.1038/nrd1470. View

Ekins S, Nikolsky Y, Nikolskaya T . Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci. 2005; 26(4):202-9. DOI: 10.1016/j.tips.2005.02.006. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

Liu X, Chen C . Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel. 2005; 8(4):505-12. View

Dykens J, Will Y . The significance of mitochondrial toxicity testing in drug development. Drug Discov Today. 2007; 12(17-18):777-85. DOI: 10.1016/j.drudis.2007.07.013. View

Oldendorf W . Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res. 1970; 24(2):372-6. DOI: 10.1016/0006-8993(70)90123-x. View

10.

Olson H, Betton G, Robinson D, Thomas K, MONRO A, Kolaja G . Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000; 32(1):56-67. DOI: 10.1006/rtph.2000.1399. View

11.

Ball P, Mandell L, Niki Y, Tillotson G . Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999; 21(5):407-21. DOI: 10.2165/00002018-199921050-00005. View

12.

Elmquist W, Sawchuk R . Application of microdialysis in pharmacokinetic studies. Pharm Res. 1997; 14(3):267-88. DOI: 10.1023/a:1012081501464. View

13.

Rodriguez-Enriquez S, Juarez O, Rodriguez-Zavala J, Moreno-Sanchez R . Multisite control of the Crabtree effect in ascites hepatoma cells. Eur J Biochem. 2001; 268(8):2512-9. DOI: 10.1046/j.1432-1327.2001.02140.x. View

14.

Begley D, Lechardeur D, Chen Z, Rollinson C, Bardoul M, Roux F . Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. J Neurochem. 1996; 67(3):988-95. DOI: 10.1046/j.1471-4159.1996.67030988.x. View

15.

Hurko O, Ryan J . Translational research in central nervous system drug discovery. NeuroRx. 2006; 2(4):671-82. PMC: 1201324. DOI: 10.1602/neurorx.2.4.671. View

16.

Kaitin K . Obstacles and opportunities in new drug development. Clin Pharmacol Ther. 2008; 83(2):210-2. DOI: 10.1038/sj.clpt.6100462. View

17.

Stoughton R, Friend S . How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov. 2005; 4(4):345-50. DOI: 10.1038/nrd1696. View

18.

El-Bacha R, Minn A . Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand). 1999; 45(1):15-23. View

19.

Khetani S, Bhatia S . Microscale culture of human liver cells for drug development. Nat Biotechnol. 2007; 26(1):120-6. DOI: 10.1038/nbt1361. View

20.

Schuster D, Laggner C, Langer T . Why drugs fail--a study on side effects in new chemical entities. Curr Pharm Des. 2005; 11(27):3545-59. DOI: 10.2174/138161205774414510. View